Resilience to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, CA, January 4, 2024 – National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:00 a.m. PST, and the Company will participate in strategic meetings with pharma and biotech customers and partners, as well as investors.
About Resilience
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell/ gene therapy modalities and drug product). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https://resilience.com/ and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.
Media Contacts:
Michele Roberts
Head of Communications
Michele.roberts@resilience.com
(888) 737-2460
Tatjana Heller
VP, Head of Investor Relations and Business Development
Tatjana.heller@resilience.com
(888) 737-2460
Source: National Resilience, Inc.
